News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
The Sozosei Foundation, a charitable foundation funded by Otsuka America Pharmaceutical, Inc., awarded $100,000 to the American India Foundation (AIF) COVID-19 Response Fund. This grant is drawn from Sozosei’s Disaster Relief and Recovery Philanthropy Program in response to India’s state of emergency, as the country records the highest number of cases and virus-related deaths globally.
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce the decision to continue the recruitment of patients in the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type (NCT03548584). The decision to continue the trial is based on the results of an independent interim analysis, supporting to progress the trial to the planned full enrollment of 330 patients.
Otsuka Pharmaceutical Co., Ltd. announces that its collaborator Akebia Therapeutics, Inc. has submitted a New Drug Application to the Food and Drug Administration in the U.S. seeking approval for Akebia’s investigational drug vadadustat as an oral medication for the treatment of renal anemia due to chronic kidney disease in adult patients who receive dialysis and those who do not receive dialysis.
Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Click Therapeutics, Inc. announce the initiation of the Mirai study, a landmark fully remote clinical trial to investigate the effectiveness of digital therapeutics in reducing depressive symptoms in adults diagnosed with major depressive disorder (MDD) who are on antidepressant monotherapy.